SPONSORED CONTENT
The 340B statute was written as a drug pricing program that outlines specifically what manufacturers are required to charge qualified covered entities for their drugs based on a defined formula. The intent of the 340B program is to help these safety net entities stretch their scarce resources to maintain and enhance services in underserved areas and reach more eligible patients.
Though the statute is silent on how much these entities should charge their patients for their drugs or the delivery mechanisms used to get pharmacy services to their patients, there is increasing scrutiny on these areas from manufacturers and other opponents of this vital program.
The Issues Surrounding 340B Pricing
Although it is not a requirement of the statute, many falsely point to 340B prices not being passed on directly to patients as a blatant misuse of the program. There are numerous reasons this was
…
